IL157389A0 - A pharmaceutical formulation comprising bicalutamide and an enteric polymer and use thereof as a medicament - Google Patents

A pharmaceutical formulation comprising bicalutamide and an enteric polymer and use thereof as a medicament

Info

Publication number
IL157389A0
IL157389A0 IL15738902A IL15738902A IL157389A0 IL 157389 A0 IL157389 A0 IL 157389A0 IL 15738902 A IL15738902 A IL 15738902A IL 15738902 A IL15738902 A IL 15738902A IL 157389 A0 IL157389 A0 IL 157389A0
Authority
IL
Israel
Prior art keywords
bicalutamide
medicament
pharmaceutical formulation
enteric polymer
enteric
Prior art date
Application number
IL15738902A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0104749A external-priority patent/GB2372444A/en
Priority claimed from SE0102572A external-priority patent/SE0102572D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL157389A0 publication Critical patent/IL157389A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15738902A 2001-02-27 2002-02-22 A pharmaceutical formulation comprising bicalutamide and an enteric polymer and use thereof as a medicament IL157389A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0104749A GB2372444A (en) 2001-02-27 2001-02-27 A pharmaceutical formulation comprising bicalutamide and a hydroxypropylmethylcellulose polymer
SE0102572A SE0102572D0 (sv) 2001-07-19 2001-07-19 Pharmaceutical formulation
PCT/GB2002/000766 WO2002067893A2 (fr) 2001-02-27 2002-02-22 Preparation pharmaceutique

Publications (1)

Publication Number Publication Date
IL157389A0 true IL157389A0 (en) 2004-05-12

Family

ID=26245766

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15738902A IL157389A0 (en) 2001-02-27 2002-02-22 A pharmaceutical formulation comprising bicalutamide and an enteric polymer and use thereof as a medicament

Country Status (22)

Country Link
US (1) US20040067257A1 (fr)
EP (1) EP1368001B1 (fr)
JP (2) JP3548566B2 (fr)
KR (1) KR20030077042A (fr)
CN (1) CN1503662A (fr)
AR (1) AR032912A1 (fr)
AT (1) ATE307571T1 (fr)
CA (1) CA2439366A1 (fr)
CZ (1) CZ20032225A3 (fr)
DE (1) DE60206889T2 (fr)
EE (1) EE200300416A (fr)
HU (1) HUP0302847A3 (fr)
IL (1) IL157389A0 (fr)
IS (1) IS6915A (fr)
MX (1) MXPA03007641A (fr)
NO (1) NO20033785L (fr)
NZ (1) NZ527532A (fr)
PL (1) PL365746A1 (fr)
RU (1) RU2003128971A (fr)
SK (1) SK10722003A3 (fr)
UY (1) UY27186A1 (fr)
WO (1) WO2002067893A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
TWI355276B (en) * 2003-01-14 2012-01-01 Akira Tsuji Gastrointestinal absorption enhancer mediated by p
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
WO2005074991A1 (fr) * 2004-02-09 2005-08-18 Kabushiki Kaisha Sangi Agent antitumoral
KR100539706B1 (ko) * 2005-01-25 2005-12-28 지엘팜텍 주식회사 타크로리무스 및 장용성 고분자를 함유하는 고체분산체
JP2008531531A (ja) * 2005-02-23 2008-08-14 アストラゼネカ アクチボラグ 方法
JP5097540B2 (ja) * 2005-04-06 2012-12-12 株式会社サンギ 腸管吸収用抗腫瘍剤
US7785629B2 (en) * 2005-06-21 2010-08-31 Helm Ag Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
US20080045600A1 (en) * 2006-08-17 2008-02-21 Gawande Rahul S Bicalutamide compositions
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JPWO2009038112A1 (ja) 2007-09-21 2011-01-06 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤
JP5204452B2 (ja) * 2007-10-02 2013-06-05 日医工株式会社 ビカルタミド含有製剤
EP2219624A2 (fr) * 2007-11-08 2010-08-25 Glaxo Group Limited Préparations pharmaceutiques
CN105237530A (zh) 2009-04-03 2016-01-13 豪夫迈罗氏公司 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟-苯基}-酰胺组合物及其用途
CN101987086B (zh) * 2009-08-03 2012-07-18 北京化工大学 一种超细比卡鲁胺口服片剂及其制备方法
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
WO2011057022A1 (fr) 2009-11-06 2011-05-12 Plexxikon, Inc. Composés et méthodes de modulation des kinases et leurs indications d'emploi
JP6109574B2 (ja) 2009-12-18 2017-04-05 カタラン、フランス、バインハイム、ソシエテ、アノニムＣａｔａｌｅｎｔ Ｆｒａｎｃｅ Ｂｅｉｎｈｅｉｍ Ｓａ 合成オリゴサッカリドを含有する医薬経口剤形
CN102525876B (zh) * 2010-12-15 2014-03-12 西安力邦医药科技有限责任公司 阿司匹林固体分散体、其制备方法、药物组合物和用途
CN102552103B (zh) * 2010-12-20 2013-11-20 西安力邦医药科技有限责任公司 拉米夫定固体分散体、其制备方法、药物组合物和用途
PT2672967T (pt) 2011-02-07 2018-12-07 Plexxikon Inc Compostos e métodos de modulação da quinase e suas indicações
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CN109897004A (zh) 2012-09-11 2019-06-18 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
JP2017523206A (ja) * 2014-08-07 2017-08-17 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤の新規製剤
EP3226843B1 (fr) 2014-12-05 2021-05-26 Aragon Pharmaceuticals, Inc. Compositions anticancéreuses
CN109646404B (zh) * 2016-12-15 2022-10-04 华领医药技术（上海）有限公司 葡萄糖激酶激活剂的口服制剂及其制备方法
CA3134550A1 (fr) 2019-04-11 2020-10-15 R.P. Scherer Technologies, Llc Formulation pour administration orale de proteines, de peptides et de petites molecules a faible permeabilite
GB2584341B (en) 2019-05-31 2023-03-01 Gw Res Ltd Cannabinoid formulations
US11344526B2 (en) 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11173291B2 (en) * 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE28864T1 (de) * 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
AU1537292A (en) * 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
EP0748220A4 (fr) * 1994-01-21 1997-09-10 Sepracor Inc Procedes et compositions de traitement de maladies dependantes des androgenes a l'aide de r-(-)-casodex optiquement pur
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
ATE324886T1 (de) * 2001-04-02 2006-06-15 Astrazeneca Ab Feste arzneizusammensetzung enthaltend 4'-cyano- trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy- 2-methylpropiono- m toluidide und pvp
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
SE0103839D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product

Also Published As

Publication number Publication date
CZ20032225A3 (cs) 2003-11-12
HUP0302847A2 (hu) 2003-12-29
EP1368001B1 (fr) 2005-10-26
CA2439366A1 (fr) 2002-09-06
EP1368001A2 (fr) 2003-12-10
NO20033785L (no) 2003-10-24
NO20033785D0 (no) 2003-08-26
SK10722003A3 (sk) 2004-02-03
DE60206889T2 (de) 2006-07-27
NZ527532A (en) 2004-12-24
IS6915A (is) 2003-08-15
JP3548566B2 (ja) 2004-07-28
JP2004143185A (ja) 2004-05-20
ATE307571T1 (de) 2005-11-15
DE60206889D1 (de) 2005-12-01
WO2002067893A3 (fr) 2003-01-16
HUP0302847A3 (en) 2005-05-30
AR032912A1 (es) 2003-12-03
EE200300416A (et) 2003-12-15
KR20030077042A (ko) 2003-09-29
MXPA03007641A (es) 2003-12-04
CN1503662A (zh) 2004-06-09
JP2004521918A (ja) 2004-07-22
UY27186A1 (es) 2002-09-30
PL365746A1 (en) 2005-01-10
WO2002067893A2 (fr) 2002-09-06
RU2003128971A (ru) 2005-03-10
US20040067257A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
IL157389A0 (en) A pharmaceutical formulation comprising bicalutamide and an enteric polymer and use thereof as a medicament
HUP0302857A3 (en) Pharmaceutical formulation
AU2002309172A1 (en) Pharmaceutical compositions containing polymer and drug assemblies
EP1367060A4 (fr) Derives glucopyranosyloxybenzylbenzene et leur utilisation medicale
EP1364957A4 (fr) Derives de glycopyranosyloxypyrazole et utilisation medicinale de ceux-ci
EP1364958A4 (fr) Derives de glycopyranosyloxypyrazole et utilisation medicinale de ceux-ci
AU3085102A (en) Drug delivery compositions and medical devices containing block copolymer
GB0118689D0 (en) Pharmaceutical formulation
PL370563A1 (en) Deuterated substituted pyrazolylbenzylsulfonamides and medicaments comprising said compounds
PL366432A1 (en) Pharmaceutical formulation
GB0322868D0 (en) A novel catalytic formulation and its preparation technical field
EP1462455A4 (fr) Nouveaux peptides et leurs utilisations en tant que medicaments
HUP0402318A3 (en) Pharmaceutical composition comprising cyclosporin and use thereof
IL161902A0 (en) Pharmaceutical formulation comprising bicalutamide
IL161306A0 (en) Pharmaceutical formulation comprising (r)-bicalutamide
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
PT1849468E (pt) Composição farmacêutica compreendendo roflumilaste levocetirizina
EP1379228A4 (fr) (z)-styrylbenzylsulfones et leurs utilisations pharmaceutiques
AU2002354070A1 (en) Medical polymers and use thereof
HUP0304063A3 (en) Medicinal compositions comprising diclofenac and ornoprostil
IL153176A (en) Phenylpiperazines and pharmaceutical compositions comprising them
AUPR548601A0 (en) Pyrazolopyrazinecompound and pharmaceutical use thereof
GB0000482D0 (en) Enteric coated pharmaceutical formulation
GB0104749D0 (en) Pharmaceutical formulation
PL370709A1 (en) Pharmaceutical formulation comprising cyclosporin and use thereof